GIVI-MPCs News, Researches, Clinical Trials and Articles

About us

We do not want children to die from a disease that can be cured. We want to give hope to families and ensure that all children with DMD are treated and regain their health.

Powered by Hostinger

Latest Articles

IPS HEART Aims to Restore Full-Length Dystrophin with Two Regenerative Cell Therapies for Duchenne Muscular Dystrophy

Press Releases August 6, 2026 0

IPS HEART has announced another important regulatory milestone after...

20 Important Things You Need to Know About DMD Genetic Testing

DMD August 1, 2026 0

DMD genetic testing for Duchenne muscular dystrophy involves analyzing...

Mutations Amenable to Exon 50 Skipping Therapies in Duchenne Muscular Dystrophy

DMD July 28, 2026 0

Mutations amenable to exon 50 skipping are an important...

Frequently Asked Questions About Elevidys Used for Duchenne Muscular Dystrophy

Approved Therapies December 26, 2024 0

A genetic condition known as Duchenne muscular dystrophy (DMD)...

Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy

Editorials April 10, 2026 0

The landscape of potential new gene therapies for Duchenne...

The Brutal Truth: Why Duchenne Muscular Dystrophy Treatment Costs Are Out of Control

Editorials April 6, 2026 0

The duchenne muscular dystrophy treatment cost has become one...

Duchenne MD

Genetic

Care Guidelines

Health Guidelines

GIVI-MPCs

Must Read

Precision BioSciences Announced the Start of Phase 1/2a (FUNCTION-DMD) Study of PBGENE-DMD in Ambulatory Patients with Duchenne

PBGENE-DMD Gene Editing Therapy: Benefits, Eligibility, and FAQs

European Commission Grants Orphan Drug Designation to SGT-003 for Duchenne Muscular Dystrophy